What are the types of 100 targeted drugs?
According to their chemical structure and mechanism of action, targeted drugs can be divided into the following categories: 1. ** Small Molecules Target Drug **: - ** Tyrosin Kinase Inhibition (TKIs)**: Commonly used in the treatment of lung cancer and other types of cancer. For example, gefitinib, erlotinib, afartinib, osimertinib, etc., which are used for the treatment of lung cancer and can be used when the patient has an egfr-gene mutation; they are also used for other cancer, such as erlotinib in the treatment of intestinal cancer. - ** Multi-Kinase Inhibition **: For example, sorafenib, sunitini, and lenvatini for the treatment of primary liver cancer. 2. ** High-molecular targeted drug **: - ** Monoclone Antibodies (MAb)**: For example, bevacizumi, which is used to treat non-small cell lung cancer and large intestine cancer, targets tumor vasculature, but it often needs to be combined with chemotherapy drugs to achieve better efficacy. There are also trastuzumi, cetuxed, etc., which are used to treat gastric cancer. - ** Immune suppressors (some are targeted, such as PD-L1 and PD-L1)**: It can suppress the binding of the PD-L1 protein on the surface of tumor cells to the PD-L1 protein on the surface of T cells, so that T cells can normally play a role in resisting tumor cells. However, the information provided so far did not clearly mention the specific types of 100 targeted drugs. The above main types could only be summarized from common targeted drugs. Read more exciting novels for free
What are the types of targeted drugs in Henan?
It was known that 17 targeted drugs, including osimertinib, crizotinib, anlotinib, and afartinib, had entered the scope of reimbursement for Henan medical insurance, but it was impossible to determine all types of targeted drugs in Henan based on the available information. However, the common targeted drugs were the first-generation gefitini and erlotini, the second-generation aflatini and dacomitini, and the third-generation osimertinib. Monocentric antibody-type molecular targeted drugs such as trastuzumb (Herceptin), Rituexiu (Mebthera), EMC-C225 (cetoxieb, Erbitux), and Bevacizu (Avastin). Small molecular compounds were commonly used, such as Glivec (ST51, Imatini), Iressa (ZD1839, Gefitini), and OSI774 (Erlotini, Tarcava). <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
There are several types of breast cancer targeted drugs
There were mainly the following types of breast cancer targeted drugs: 1. Anti-neoplastic targeted drugs: There are intravenous preparations and oral drugs, but the effect in the treatment of breast cancer is not ideal. For example, bevacidol (Avastin) will be considered in some cases. 2. Anti-Her- 2 targeted drugs: targeted at HER - 2 positive patients, it is the most important targeted drug for breast cancer, mainly including trastuzumab (Herceptin), pertubizab, dm- 1, lapatini, etc. The prerequisite for use was that the patient was positive for HER - 2 (+++ in the immune tissue test). If the immune tissue test was ++, the patient would need to undergo a further FISH test. The patient could only be used if the FISH test was positive. If the immune tissue test was + or-, the patient could not be used. 3. A targeted drug for patients with fetal mutations in the Brca lineage: The main drug is olaparib, which is used to treat patients with metastasizing breast cancer who have harmful or suspected harmful mutations in the Brca lineage and who are negative for the human embryonic growth factor receptor 2 (HEL2). 4. Immune therapy (in a sense, it was also a targeted drug): Anti-PD- 1/PD-L1 Monoclone Antibodies, which essentially relieved immune suppression and activated immune cells to kill cancer cells. 5. mTO inhibition drugs, such as everolimus and sirolimus, can inhibit the activation of the mTO signaling pathway, thereby suppressing the growth and metabolism of tumor cells. 6. Other targeted therapy drugs, such as Parp inhibition drugs, CD 4/6 inhibition drugs, etc. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
There are several types of targeted drugs for mutations in adenomas.
The common driver gene mutations in lung adenomas include mutations in the Epidermal Growth factor receptor gene (EGFR), the anplastic leukemia kinases gene (ALK), the Kirsten rat sarcomas virus gene homolog gene mutation (KRAS), the c-ros proto-oncogene 1 Tyrosin Kinase gene mutation (ROS1), and the RET gene mutation. The corresponding targeted drugs were as follows: 1. ** Mutant of the egFPR gene **: The corresponding targeted drug is egFR-TKi. Mutations in the EGFR gene were more likely to occur in Asians, women, and non-smoking patients with cancerous tumors. Mutations were more common in the exons of the 18th to 21st genes. The total incidence of mutations in the 19th and 21st exons was about 90%. In addition, there were also mutations in the 20 exons of the EGFR gene, but the treatment situation was special. The first-generation and second-generation targeted drugs were not very effective. If the first-line chemotherapy was not effective, the targeted drug bozitini, which was specifically targeted at the 20 exons of the EGFR gene, would be used for treatment. If the drug was resistant, the third-generation targeted drug, amitini, might be used. 2. **ALK Gene Rearrangement **: It usually appears in the form of the fusion gene EML4- ALK. The corresponding targeted drug is not specified, but studies have shown that this gene rearranging is rare. In Asian lung cancer patients, the occurrence rate is 3% - 5%, and it is mostly seen in young people without a history of smoking. 3. **Kras gene mutation **: It was one of the earliest cancer-causing genes that mutated in human cancer, but the article did not mention specific targeted drugs for Kras gene mutation. In China, 8% - 10% of lung cancer patients had Kras gene mutation, and it was related to smoking history. 4. ** ROS1 Gene Rearrangement **: The production of new fusion kinases can lead to malignant tumors. Although the ROS1 gene is only expressed in 1% - 2% of patients with lung cancer, there are still 10,000 - 15,000 patients with lung cancer who have ROS1 gene rearrangements every year. The corresponding types of targeted drugs are not mentioned in the article. 5. **RET gene mutation **: The corresponding targeted drugs mainly include vandetanil, cabotanil, etc. Vandetanil was a multi-target receptor that could inhibit the signaling pathways of the vasothelin growth factor receptor 2, EGFR, and RET. Cabotini was a multi-receptor that was active against RET. It had an anti-tumor effect by blocking the proto-cancerous gene receptor, vasothelin growth factor receptor 2, and RET signaling pathways. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the characteristics of the types of targeted drugs for leukemia in the United States?
First of all, I need to correct you. Medically, it's called leukemia. There were the following types and characteristics of targeted drugs for leukemia in the United States: 1. ** Antibody-drug combinations ** - **Polivy (Polatu Bedotin)**: Target the CD 79b pathway and deliver toxic drugs to the tumor, approved for use in patients with non-Hodgkin's leukemia. - ** Brentment vedotin (Adcetris)**: targets the CD30 pathway and deliver toxic drugs to the tumor. It is approved for use in a sub-group of patients with Hodgkin's or non-Hodgkin's leukemia, including as first-line treatment. - ** Etumomab tiuxetan (Zevalin)**: Target the CD20 pathway and deliver toxic drugs to the tumor, approved for use in patients with non-Hodgkin's leukemia. 2. ** Monoclone Antibodies ** - ** Mogamulizan (Poteligeo)**: A monoclone that targets the CCR4 pathway. It is approved for use in patients with two rare types of non-Hodgkin's leukemia (fungus and Serbkin's disease), which affects the skin. - ** Obinutuzumi (Gazyva)**: Monoclone Antibodies that target the CD20 pathway, approved for use in a sub-set of patients with non-Hodgkin's leukemia, including as first-line treatment. - ** Rituxan (Rituxan)**: Monoclone Antibodies that target the CD20 pathway, approved for use in a sub-set of patients with CD20-positive non-Hodgkin's leukemia (NPC), including as first-line treatment. 3. ** Check Point Inhibition Agents (Immune Regulators)** - ** Nivioluba (Opdivo)**: A checkpoint indicator targeting the PD-L1 pathway, approved for use in a sub-set of patients with classic Hodgkin's leukemia. - ** Pembrolizan (Keytruda)**: A checkpoint indicator of the PD-L1 pathway, approved for use in a sub-set of patients with classic Hodgkin's leukemia. 4. ** Cytokines (Immune Regulators)** - ** Interferon alpha- 2b (IntronA)**: A hormone that targets the IFNAR1/2 pathway and is approved for use in a sub-set of patients with Follicular Malignity. The characteristics of these targeted drugs included: 1. ** High accuracy **: If targeted therapy only targets tumor cells and has no harmful effect on normal cells, the accuracy rate is very high. 2. [High Concentration (Strong Effect): Stronger effect on tumor cells.] <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the targeted drugs for immunity drugs?
The immune drugs mainly included nivulumab injection, pabolizuab injection, atilibizab, duvalliumab, carrelizub, etc. The targeted drugs mainly included trastubiza for injection, pertubiza injection, osimertinib, dacotinib, gefitini, erlotinib, icotinib, afartinib, etc.(There were also many targeted drugs for different cancer types, such as osimertinib and dacotinib targeted for the first-line treatment of lung cancer and lung cancer, alectinib, crizotinib, etc. for the first-line treatment of ALK mutation). <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the benefits of targeted drugs?
The targeted drugs had the following benefits: 1. Strong treatment targeting: From the molecular level of cells, drugs are designed to target specific targets on the surface of cancer cells, and more accurately act on the target to control the tumor. They only act on the target and have little effect on normal cell tissues. 2. It has remarkable efficacy: it can effectively kill tumor cells and reduce lumps. In some patients, its efficacy is no less than that of chemotherapy and chemotherapy. It can reduce the symptoms of cancer patients, improve the survival time and quality of life of cancer patients, and make cancer a chronic disease that can be treated continuously to a certain extent, helping patients survive with cancer. 3. Less side effects: Because it has little effect on normal cells and tissues, there are fewer side effects. Compared to treatments such as chemotherapy, there are no side effects of chemotherapy. For example, it will not cause large-scale destruction to normal cells in the body like chemotherapy. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Take the third generation of targeted drugs after the first generation of targeted drugs are resistant
After the first-generation targeted drug became resistant, the third-generation targeted drug could be considered. According to the data in document [2], after the first-generation targeted drug became resistant, only about 25% of patients had the opportunity to use osimertinib for second-line treatment. According to the study mentioned in document [4], the first-line use of osimertinib for the treatment of egfr-positive lung cancer, followed by comprehensive treatment methods such as chemotherapy and chemotherapy after drug resistance, the patient's overall survival time was 41.4 months, which was twice as long as the first-generation targeted drug. In addition, the document [5] mentioned the dual-target combination therapy plan, specifically the first-line treatment of the third-generation TKi osimertinib combined with the first-generation TKi gefitini, with a disease control rate of 100%. Therefore, for patients who were resistant to first-generation targeted drugs, third-generation targeted drugs might be an effective treatment option.
What are the targeted drugs that need to be tested?
In cancer treatment, genetic testing was usually needed to find suitable targets to determine whether targeted drugs could be used. For example, targeted drugs corresponding to mutations in genes such as EGFR, ALK, ROS - 1, BRAF, etc. in lung cancer needed genetic testing to determine the existence of the target before use. In addition, genetic testing was also needed to determine whether cetuxed could be used in the treatment of patients with benign or malignant tumors. However, targeted drugs such as domestic anlotinib, lenvatini, regorafenib, sorafenib, apitini, sunitini, cabotini, cediranil, bevacizumi, and olakumab, as well as bevacizumi in head and neck tumors (such as throat cancer, oral cancer, gum cancer, and other pathological squamous-cell cancer), did not require genetic testing. However, in general, it was more complicated to perform target testing for different tumor diseases and targeted drugs before use. It needed to be analyzed according to the specific situation. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the targeted drugs for serous adenomas?
For high-grade serous adenomas, targeted therapy includes anti-neoplastic targeted drugs such as bevacizumi; for relapsed low-grade serous adenomas, Novartis targeted anti-cancer drug Mekinist (Trametini) has the potential to become a treatment option. In addition, in the treatment of malignant tumors, nirapalide tosylate capsules can be used as a targeted drug for maintenance therapy. For patients who overexpress HEL2/ neu, adding trastubiza (Herceptin) to standard chemotherapy can provide a new solution to improve the prognosis. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the targeted drugs for genetic mutation?
There were many types of targeted drugs that were made based on the genetic mutation characteristics of cancer cells. For example, targeted drugs for Kras gene mutation (commonly seen in patients with Colon cancer) include gefitini, regerafenib, sorafenib, bevacizumi, etc.; targeted drugs for the treatment of ERBB2 (also known as HEL2) mutation include trastubiza, pertubiza, lapatini, etc.; For the mutation of Braf15, it is suitable to use a combination of drafenib and trametini. In addition, targeted drugs such as gefitini, icotini, osimetini, bugatini, and other drugs with clear targets (e.g., ADC, ALK, etc.) were also made based on the principle of genetic mutation. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>